Off-the-shelf platelet-derived regenerative biologic (PRB) therapy for patients with ocular surface disease, targeting Sjögren's syndrome–related dry eye. Standardized, mass-manufactured, low-cost alternative to autologous platelet-rich plasma with preclinical efficacy and scalable manufacturing for clinical development.